Pyridyl derivatives and their use as therapeutic agents

The compound of formula (IV):

• wherein:
• x and y are each independently 1;
• Va is —C(O)—;
• each R1 is independently selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12hydroxyalkyl, C4-C12cycloalkylalkyl and C7-C19aralkyl;
• R2 is selected from the group consisting of C1-C12alkyl, C2-C12alkenyl, C2-C12hydroxyalkyl, C2-C12hydroxyalkenyl, C3-C12alkoxyalkyl, C3-C12cycloalkyl, C4-C12cycloalkylalkyl, aryl, C7-C19aralkyl, C3-C12 heterocyclyl, C3-C12heterocyclylalkyl, C1-C12heteroaryl and C3-C12heteroarylalkyl;
• or R2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl, where some or all of the rings may be fused to each other;
• R3 is phenyl or naphthalene;
• R4, R5 and R6 are each independently selected from hydrogen, bromo,fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or —N(R13)2;
• R7, R7a, R8, R8a, R9, R9a, R10, and R10a are each independently selected from hydrogen or C1-C3alkyl;
• and
• each R13 is independently selected from hydrogen or C1-C6alkyl;
• a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.